Cue Biopharma Inc CUE

$4.15 -0.35 (-7.78%)

Valuation

Market cap
30,147,000
Revenue TTM
$27,470,000
Net income TTM
$-26,600,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-96.83%
Debt to equity
0.00

Trading

Volume
1,263,400
Avg volume
684,864
Day's range
$4.05 – $4.90
Shares out
7,264,000
Stochastic %K
8%
Beta
2.79
Analysts
Strong Buy
Price target
$68.67

Price

Company profile

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead au...

Show more

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 949 2680
Website
https://www.cuebiopharma.com
Address
40 Guest Street, Boston, United States

Latest news

No headlines yet.